Abstract
Protein kinase CK2, a serine/threonine kinase, is an attractive therapeutic target for many diseases. Here we described an application of cross-docking based drug design to discover novel and potent CK2 leads. Glide SP was chosen as the most suitable docking approach by comparing four docking protocols through native-docking. Then twenty-four CK2 crystal structures were compared by recovering known active ligands from a decoy database to select the optimal ensemble of CK2 structures, 2PVN, 2ZJW, 3AMY, 3FL5 and 3KXH were severed as the assemble, which were used in the virtual screening of compiled SPECS database for small molecules inhibiting CK2. Seven compounds were selected and purchased to test the biological activity. Compound g (AQ-390/42425635) showed the best inhibition rate and the lowest IC50, which can be used as a lead for our subsequent optimization.
Keywords: Protein kinase CK2 inhibitor, cross-docking, receptor-based virtual screening, biological test, lead.
Medicinal Chemistry
Title:Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening
Volume: 10 Issue: 6
Author(s): Haopeng Sun, Xiaowen Wu, Xiaoli Xu, Zhengyu Jiang, Zongliang Liu and Qidong You
Affiliation:
Keywords: Protein kinase CK2 inhibitor, cross-docking, receptor-based virtual screening, biological test, lead.
Abstract: Protein kinase CK2, a serine/threonine kinase, is an attractive therapeutic target for many diseases. Here we described an application of cross-docking based drug design to discover novel and potent CK2 leads. Glide SP was chosen as the most suitable docking approach by comparing four docking protocols through native-docking. Then twenty-four CK2 crystal structures were compared by recovering known active ligands from a decoy database to select the optimal ensemble of CK2 structures, 2PVN, 2ZJW, 3AMY, 3FL5 and 3KXH were severed as the assemble, which were used in the virtual screening of compiled SPECS database for small molecules inhibiting CK2. Seven compounds were selected and purchased to test the biological activity. Compound g (AQ-390/42425635) showed the best inhibition rate and the lowest IC50, which can be used as a lead for our subsequent optimization.
Export Options
About this article
Cite this article as:
Sun Haopeng, Wu Xiaowen, Xu Xiaoli, Jiang Zhengyu, Liu Zongliang and You Qidong, Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening, Medicinal Chemistry 2014; 10 (6) . https://dx.doi.org/10.2174/1573406409666131128143601
DOI https://dx.doi.org/10.2174/1573406409666131128143601 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Current Neuropharmacology The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Contemporary Anticholinesterase Pharmaceuticals of Natural Origin and Their Synthetic Analogues for the Treatment of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment
Current Alzheimer Research Meet Our Associate Editor
Current Molecular Medicine Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists
Current Topics in Medicinal Chemistry Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Neuropsychiatric and Cognitive Symptoms in Spinocerebellar Ataxia: Relationship to Neuropathological Differences
Current Psychiatry Reviews Patent Selections
Recent Patents on Food, Nutrition & Agriculture Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Phosphodiesterase-4 Modulation as a Potential Therapeutic for Cognitive Loss in Pathological and Non-Pathological Aging: Possibilities and Pitfalls
Current Pharmaceutical Design